Ratio de margen de beneficio operativo
desde 2005
Cálculo
Celgene Corp., ratio de margen de beneficio operativo, tendencias a largo plazocálculo
| Ratio de margen de beneficio operativo | = | 100 | × | Resultado (pérdida) de explotación1 | ÷ | Ventas netas de productos1 | |
|---|---|---|---|---|---|---|---|
| 31 dic 2018 | 34.01% | = | 100 | × | 5,191) | ÷ | 15,265) |
| 31 dic 2017 | 36.28% | = | 100 | × | 4,707) | ÷ | 12,973) |
| 31 dic 2016 | 28.31% | = | 100 | × | 3,167) | ÷ | 11,185) |
| 31 dic 2015 | 24.61% | = | 100 | × | 2,255) | ÷ | 9,161) |
| 31 dic 2014 | 33.30% | = | 100 | × | 2,519) | ÷ | 7,564) |
| 31 dic 2013 | 28.43% | = | 100 | × | 1,809) | ÷ | 6,362) |
| 31 dic 2012 | 32.43% | = | 100 | × | 1,746) | ÷ | 5,386) |
| 31 dic 2011 | 30.70% | = | 100 | × | 1,443) | ÷ | 4,700) |
| 31 dic 2010 | 28.21% | = | 100 | × | 990) | ÷ | 3,508) |
| 31 dic 2009 | 32.78% | = | 100 | × | 842) | ÷ | 2,567) |
| 31 dic 2008 | -68.50% | = | 100 | × | (1,464) | ÷ | 2,138) |
| 31 dic 2007 | 32.69% | = | 100 | × | 425) | ÷ | 1,300) |
| 31 dic 2006 | 21.52% | = | 100 | × | 175) | ÷ | 812) |
| 31 dic 2005 | 18.76% | = | 100 | × | 84) | ÷ | 446) |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).
1 US$ en millones
Comparación con la competencia
Celgene Corp., ratio de margen de beneficio operativo, tendencias a largo plazo, comparación con los competidores
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| 31 dic 2018 | 34.01% | 19.49% | 45.55% | 17.11% | 37.83% | 37.77% | 15.53% | 20.84% |
| 31 dic 2017 | 36.28% | 33.99% | 45.76% | 16.48% | 55.04% | 35.41% | 14.19% | 4.95% |
| 31 dic 2016 | 28.31% | 36.60% | 44.74% | 16.29% | 58.87% | 27.38% | 13.40% | 0.58% |
| 31 dic 2015 | 24.61% | 32.97% | 40.44% | 16.87% | 69.03% | 30.51% | 13.77% | -45.23% |
| 31 dic 2014 | 33.30% | 17.09% | 32.03% | 17.23% | 62.37% | 29.74% | 14.82% | -119.30% |
| 31 dic 2013 | 28.43% | 30.14% | 32.25% | 17.13% | 41.87% | 36.11% | 12.30% | -74.54% |
| 31 dic 2012 | 32.43% | 31.65% | 33.52% | 17.33% | 42.67% | 33.20% | 11.85% | 0.15% |
| 31 dic 2011 | 30.70% | — | 28.19% | 16.27% | 46.77% | -46.02% | 10.62% | 8.07% |
| 31 dic 2010 | 28.21% | — | 37.82% | 16.41% | 53.62% | -21.23% | 11.72% | -485.51% |
| 31 dic 2009 | 32.78% | — | 38.37% | 13.79% | 54.55% | -19.54% | 10.38% | -602.63% |
| 31 dic 2008 | -68.50% | — | 35.50% | 14.72% | 52.68% | -37.67% | 11.71% | -263.65% |
| 31 dic 2007 | 32.69% | — | 27.81% | 15.79% | 57.98% | -91.55% | 10.00% | -210.94% |
| 31 dic 2006 | 21.52% | — | 27.71% | 15.82% | -29.32% | -169.68% | 6.38% | -105.86% |
| 31 dic 2005 | 18.76% | — | 40.33% | 15.84% | 61.41% | -187.97% | 10.01% | -93.15% |
Basado en los informes: 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31), 10-K (Fecha del informe: 2011-12-31), 10-K (Fecha del informe: 2010-12-31), 10-K (Fecha del informe: 2009-12-31), 10-K (Fecha del informe: 2008-12-31), 10-K (Fecha del informe: 2007-12-31), 10-K (Fecha del informe: 2006-12-31), 10-K (Fecha del informe: 2005-12-31).